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Abstract
Introduction: At present, little data exists about the incidence of, and the risk factors associated with, metabolic syndrome (MetS) in pa-
tients with type 2 diabetes mellitus (T2DM). The aims of this present study were to assess the incidence and risk factors of MetS in people 
with T2DM using routinely collected data from a clinical information system at Isfahan Endocrine and Metabolism Research Centre, Iran.
Material and methods: During the mean (SD) follow-up period of 11.7 (4.8) years, 3,047 patients with T2DM who were free of MetS at 
baseline were examined to determine the incidence and predictors of progression to MetS. The mean (SD) age of participants was 50.4 
(11.0) years, with a mean (SD) duration of diabetes of 6.3 (6.2) years at initial registration. A modified National Cholesterol Education 
Programme- Adult Treatment Panel III definition (with body mass index [BMI] instead of waist circumference) was used for the MetS.
Results: The prevalence of MetS was 63.2% (95% CI: 62.3, 64.1). The incidence of MetS was 28.5 (95% CI: 26.8, 30.2) (25.9 men and 30.9 
women) per 1,000 patient-years based on 35,677 patient-years of follow-up. Multivariate analysis revealed that higher body mass index 
(BMI) and education, lower HbA1c and treatment with oral agent or insulin were associated with MetS.
Conclusions: These are the first estimates of the incidence and risk factors of MetS in patients with T2DM in Iran. These findings show 
that the natural course of MetS is dynamic. The clinical management of patients with T2DM will contribute significantly to MetS preven-
tion. (Pol J Endocrinol 2012; 63 (5): 372–380)
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Streszczenie
Wstęp: Obecnie dostępnych jest niewiele danych dotyczących zapadalności na zespół metaboliczny (MetS) i związanych z nim czynników 
ryzyka u chorych na cukrzycę typu 2 (T2DM). Niniejsze badanie przeprowadzono w celu oceny zapadalności na MetS i występowania 
czynników ryzyka tego zespołu u chorych na cukrzycę typu 2 na podstawie rutynowych danych gromadzonych w systemie informacji 
klinicznej w Isfahan Endocrine and Metabolism Research Centre w Iranie.
Materiał i metody: W ciągu okresu obserwacji, trwającego średnio (SD) 11,7 (4,8) roku, przebadano 3047 chorych na T2DM, u których 
wyjściowo nie stwierdzono cech MetS, w celu określenia zapadalności i czynników predykcyjnych progresji do MetS. Średnia wieku (SD) 
uczestników wynosiła 50,4 (11,0) roku, a średni czas trwania (SD) cukrzycy w momencie pierwszej rejestracji danych — 6,3 (6,2) roku. 
Rozpoznanie MetS ustalano na podstawie zmodyfikowanej definicji National Cholesterol Education Programme — Adult Treatment Panel III 
(w której uwzględniono wskaźnik masy ciała [BMI] zamiast obwodu talii).
Wyniki: Częstość występowania MetS w badanej populacji wynosiła 63,2% (95% CI: 62,3–64,1). Wskaźnik zapadalności na MetS wynosił 
28,5 (95% CI: 26,8–30,2) (25,9 dla mężczyzn i 30,9 dla kobiet) na 1000 pacjentolat, co wyliczono na podstawie obserwacji obejmującej 
35 677 pacjentolat. W analizie wieloczynnikowej wykazano, że wyższe wartości BMI, wyższy poziom wykształcenia, niższe HbA1c i leczenie 
doustnymi lekami hipoglikemizującymi oraz insuliną wiązały się z MetS.
Wnioski: W niniejszej pracy po raz pierwszy oszacowano zapadalność na MetS i określono czynniki ryzyka rozwoju tego zespołu 
u pacjentów z T2DM w Iranie. Uzyskanie rezultaty wskazują, że naturalny przebieg MetS jest procesem dynamicznym. Odpowiednie 
leczenie chorych na T2DM może mieć istotne znaczenie w zapobieganiu MetS. (Endokrynol Pol 2012; 63 (5): 372–380)
Słowa kluczowe: cukrzyca, zapadalność, zespół metabolicznych, czynniki ryzyka
Introduction
Metabolic syndrome (MetS) is an important public 
health problem worldwide, and its prevalence is 
increasing [1, 2]. Patients with MetS are at higher 
risk for many long-term complications, including 
micro- and macro-vascular complications [2]. This is 
particularly relevant in patients with type 2 diabetes 
mellitus (T2DM), who are at even greater cardiovas-
cular risk [3]. In fact, cardiovascular complications 
are the commonest cause of morbidity and mortality 
in patients with T2DM [4].
373
Endokrynologia Polska/Polish Journal of Endocrinology 2012; 63 (5)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
The relationship between MetS and diabetes and 
cardiovascular disease is well established and consistent 
and has been examined in many different populations 
[3, 5, 6]. T2DM and cardiovascular disease have many 
risk factors in common, and many of these risk factors 
are highly correlated with one another [5, 7]. MetS is 
very common among patients with T2DM; using the 
Third Report of the National Cholesterol Education 
Programme Adult Treatment Panel (NCEP/ATP III) 
definition, over 65% of patients with T2DM have MetS 
[8]. This is a much higher prevalence than in comparable 
general populations [9, 10]. The higher prevalence of 
MetS in patients with T2DM may be explained by medi-
cation-, disease- and lifestyle-related factors. Limited 
information is available about the incidence of MetS and 
its risk factors in patients with T2DM, and no informa-
tion whatever in Iran.
Accurate information regarding the incidence of 
MetS and associated risk factors in people with T2DM 
is important in order to get a better understanding of 
the natural course of metabolic and cardiovascular 
risk in a non-pre-selected cohort of diabetic patients in 
routine practice.
This study therefore used routinely collected data 
from a clinical information system for diabetes at Isfahan 
Endocrine and Metabolism Research Centre, Iran, to 
estimate the incidence of MetS and to identify its risk 
factors in a large sample of diabetic patients receiving 
routine care.
Material and methods
Participants and data collection
The recruitment methods and examination procedures 
of the Isfahan Endocrine and Metabolism Research Cen-
tre outpatient clinics have been previously described 
[11, 12]. In summary, clinical data was collected for 
all consecutive patients at the first attendance and at 
review consultations (usually annual) using standard 
encounter forms. These included an examination of 
ocular fundus and lens, the limbs, and blood pressure 
(BP), and measurement of height, weight, fasting plas-
ma glucose (FPG), glycosylated haemoglobin (HbA1c), 
urine protein, and triglyceride, cholesterol, and serum 
creatinine levels. The clinician compiled a list of prob-
lems, and smoking was reported via a questionnaire 
completed by each patient on demography, family 
history, and smoking.
Generally, newly diagnosed patients were referred 
to qualified nutritionists for evaluation; if necessary, 
a lifestyle and weight management programme was 
recommended. All newly diagnosed patients at-
tended weight-related health education classes, free 
of charge.
Participants
Using routinely collected data from a clinical infor-
mation system at Isfahan Endocrine and Metabolism 
Research Centre, Iran, we performed a retrospective 
longitudinal, observational study. The study popula-
tion consisted of all prevalent cases of T2DM and all 
patients diagnosed during the study period. Between 
1992 and 2009, a total of 11,281 patients with T2DM 
were registered in the system. However, this study uses 
data only for 3,047 of these patients, i.e. 1,461 (47.9%) 
men and 1,586 (52.1%) women who had at least one 
subsequent review since registration and who were free 
of MetS at baseline. The physician defined the type of 
diabetes according to the American Diabetes Associa-
tion criteria [13].
Our study conformed to the Declaration of Helsinki. 
Institutional ethical committee approval was granted, 
and an informed consent was signed by each patient.
Ascertainment of MetS
A minimally modified NCEP/ATP III [14] definition, 
with body mass index (BMI) instead of waist circum-
ference, was used for MetS, with the presence of 
three or more of the following abnormalities: blood 
pressure ≥ 130/85 mm Hg or a history of hyperten-
sion and current use of antihypertensive treatment; 
BMI ≥ 25 kg/m2; serum triglyceride ≥ 150 mg/dL 
(≥ 1.7 mmol/L); high-density lipoprotein choles-
terol (HDL; < 40 mg/dL (< 0.9 mmol/L) for men 
and < 50 mg/dL (< 1.0 mmol/L) for women); and known 
diabetes mellitus. BMI ≥ 25 kg/m2 was used because 
waist circumference was not available. In some other 
studies, BMI has been adopted instead of waist circum-
ference for the analysis of MetS [5, 8, 15, 16].
Procedures
Predictors of progression to MetS were assessed using 
the following data from the patient’s registration consul-
tation: gender, age at diagnosis (i.e. at the time this was 
first recorded by a physician on the participant’s chart), 
current age (at the time of examination), educational 
level, duration of diabetes (the time between diagnosis 
and the baseline examination), BMI (weight/height2 
[kg/m2]), smoking status (never or current), HbA1c 
(measured by ion-exchange chromatography), FPG 
(measured by the glucose oxidase method, Clinical 
Chemistry Analyzer Liasys, Italy), proteinuria (meas-
ured by precipitation with 3% sulfosalicylic acid and 
determination of turbidity by measuring absorbance 
at a wavelength of 550 nm with a spectrophotometer), 
and levels of serum creatinine, triglyceride, cholesterol, 
HDL (measured using standardised procedures), and 
low-density lipoprotein cholesterol (LDL; calculated by 
the Friedewald Equation [17]).
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Height and weight were measured using standard 
apparatus, with the subjects in light clothes and without 
shoes. Weight was measured to the nearest 0.1 kg on 
a calibrated beam scale. Height was measured to the 
nearest 0.5 cm, and assessed at baseline only. A physi-
cian measured the systolic and diastolic BPs of the par-
ticipants (after they had been seated for ten minutes) 
using a mercury sphygmomanometer and standard 
techniques. All clinical and laboratory measurements 
at baseline and follow-ups were made using the same 
standardised protocol.
Determination of MetS incidence
Incidence of MetS was expressed as the number of cases 
of MetS per 1,000 patient-years of follow-up. As the 
relevant period, we considered the date of completion 
of the baseline examination between 1992 and 2009 
until one of the following four events: a) occurrence 
of MetS; b) the date of the last completed follow-up; 
c) death; or iv) the end of the follow-up on December 
31, 2009, whichever came first.
Statistical analysis
The statistical methods used included the Student’s 
T-test; chi squared test, analysis of variance (ANOVA) 
or Kruskal-Wallis tests for normally or non-normally 
distributed continuous variables respectively and Cox’s 
proportional hazards model. Univariate and multivari-
ate Cox’s proportional hazards models were fitted to 
identify predictors of new-onset MetS using SPSS ver-
sion 18 for Windows (SPSS Inc., Chicago, IL, USA). All 
the significant variables in the bivariate analysis were 
included as independent variables in a multivariate 
Cox’s proportional hazards models. Adjustment for 
age was examined in separate models. Age-adjusted 
means were calculated and compared using general 
linear models. All tests for statistical significance were 
two-tailed, confidence intervals (CI) were set at 95% 
and p < 0.05 was considered significant.
Results
Subject characteristics
Differences in distribution of several risk factors among 
1,461 men and 1,586 women are shown in Table I. 
Women had slightly lower creatinine, were less likely 
to be smokers, and were younger at registration and 
had lower dyslipidaemia than men. Men had lower 
BMI, total cholesterol, HDL and LDL cholesterol than 
women. The mean (SD) BMI was 24.0 (3.3) for men and 
25.7 (4.3) for women. The prevalence of overweight 
(BMI ≥ 25) was 25.1% (95% CI: 22.7, 27.4%) in men, and 
45.1% (95% CI: 42.5, 47.8%) in women. Only 8.1% (95% 
CI: 6.7, 9.8%) of men and 5.10% (95% CI: 4.0, 6.4%) of 
women were underweight (BMI ≤ 20). The majority of 
patients were on oral agent (61.0%), and 22.6% of the 
sample was on diet and exercise; 16.4% of the patients 
were on insulin treatment.
Prevalence
As defined by the modified NCEP/ATP III criteria, of 
the 11,281 patients with T2DM, 7,132 (2,584 men and 
4,548 women) had MetS. The overall prevalence of 
MetS was 63.2% (95% CI: 62.3, 64.1). Prevalence rates 
were higher in women (68.8% [95% CI: 67.7, 69.9]) 
Table I. Age and age-adjusted means (SE) and proportions of 
selected characteristics among 1,461 men and 1,586 women
Tabela I. Średnie i skorygowane względem wieku wartości 
(SE) wybranych parametrów i ich rozkład w grupie 1461 
mężczyzn i 1586 kobiet
Variables Men Women
Mean (SE) Mean (SE)
Age at registration (yr.) 52.3 (0.28) 48.7 (0.27)**
Duration of diabetes (yr.) 6.5 (0.16) 6.2 (0.15)
Age at diagnosis (yr.) 43.9 (0.16) 44.2 (0.15)
BMI [kg/m2] 24.0 (0.11) 25.7 (0.10)**
Systolic BP [mm Hg] 116.1 (0.37) 115.1 (0.35)*
Diastolic BP [mm Hg] 72.0 (0.27) 71.8 (0.25)
Fasting blood glucose [mg/dL] 203.4 (2.11) 199.0 (2.02)
HbA1c (%) 8.8 (0.10) 8.5 (0.10)*
Creatinine [mg/dL] 1.04 (0.03) 0.88 (0.02)**
Triglycerides [mg/dL] 164.2 (3.21) 156.0 (3.10)
Cholesterol [mg/dL] 201.0 (1.25) 213.1 (1.20)**
HDL cholesterol [mg/dL] 46.9 (0.66) 55.8 (0.66)**
LDL cholesterol [mg/dL] 118.4 (2.32) 126.6 (2.34)*
% %
Obesity (BMI ≥ 30)
Current smoker 32.5 2.6**
Dyslipidaemia† 37.1 32.6*
Therapeutic regimen 
Diet 21.7 23.4*
Oral agent 61.5 60.6
Insulin 16.9 16.1
Education
Primary or below 46.7 72.2**
Secondary 32.3 22.2
Matriculation or above 21.0 5.6
*p < 0.05, **p < 0.001, †dyslipidaemia: triglyceride ≥ 150 mg/dL  
(≥ 1.7 mmol/L) or HDL cholesterol < 40 mg/dL (< 0.9 mmol/L)  
in men or < 50 mg/dL (< 1.0 mmol/L) in women; BP — blood pressure; 
HDL — high-density lipoprotein cholesterol; LDL — low-density 
lipoprotein cholesterol
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than men (55.3% [95% CI: 53.9, 56.8]). The prevalence 
of MetS increased with age. Of the 1,412 patients who 
had been insulin-treated, 772 had MetS, giving a preva-
lence of 54.7% (95% CI: 52.1, 57.3). This was lower than 
the prevalence rate for non-insulin-treated, which was 
66.3% (95% CI: 65.3, 67.2).
Most diabetic patients had three components of the 
syndrome (36.4%); 23.4% had four, and 3.4% had five 
components. Only 9.2% of the diabetic patients were 
free from any components of the syndrome, and 27.6% 
had one component.
Incidence
Of the 3,047 participants without MetS, 1,017 (33.4%) 
(446 men and 571 women) developed MetS in 35,677 
(17,205 men and 18,472 women) patient-years of 
follow-up. The overall incidence of subsequent 
MetS was 28.5 (95% CI: 26.8, 30.2) per 1,000 pa-
tient-years. Incidence rates were higher in women (30.9 
[95% CI: 28.4, 33.4]) per 1,000 patient-years) than men 
(25.9 [95% CI: 23.5, 28.3]). This difference was statisti-
cally significant (p < 0.01). Of the 501 patients who 
had been insulin-treated, 174 subsequently developed 
MetS, giving an incidence of 30.1 per 1,000 patient-years 
(95% CI: 25.7, 34.5). This was similar to the incidence 
rate seen for oral agent-treated, which was 29.4 per 
1,000 patient-years (95% CI: 27.2, 31.7), but slightly 
higher than the incidence rate seen for exercise and diet 
treated, which was 24.9 (95% CI: 21.0, 28.2).
Risk factors
Table II shows the group means (SE) and proportions 
for those who did, and did not, develop MetS. Those 
who developed MetS were more often women and had 
higher weight, BMI, cholesterol, number of follow-up 
visits and proportion of obesity at baseline. Those who 
did not develop MetS were more likely to be smokers 
and had slightly higher follow-up period, height, and 
educational level than those who developed MetS.
Univariate analysis (Table III) showed age, gender, 
lower HbA1c, BP, triglyceride, oral antihyperglycaemic 
therapy, overweight and obesity, and never smoking, to 
be significantly associated with the risk of developing 
MetS. Age-adjusted Cox regression coefficient among 
those free of MetS at registration showed that significant 
risk factors for developing MetS were: shorter duration 
of diabetes, lower FPG, cholesterol, triglyceride, creati-
nine, never smoking, higher education, oral agent or 
insulin treatment, and overweight and obesity.
The incidence of MetS was also analysed with 
multivariate model. Cox’s proportional hazards model 
showed that higher BMI (RR 1.04; 95% CI: 1.03, 1.05), 
higher education (RR 1.48; 95% CI: 1.29, 1.69), and 
lower HbA1c (RR 0.90; 95% CI: 0.88, 0.93), and treatment 
with insulin (RR 1.22; 95% CI: 1.10, 1.35) or oral agent 
(RR 1.25; 95% CI: 1.09, 1.43) at baseline significantly 
predicted the onset of MetS after a mean 11.7 years. No 
other variables were significant.
Discussion
In this follow-up study of 3,047 participants, the natural 
course of MetS in patients with T2DM was described. 
The incidence of MetS was 28.5 per 1,000 patient-years 
over an average follow-up of 11.7 years. The incidence 
rates were 25.9 per 1,000 patient-years in men and 
30.9 in women. It seems that the higher the BMI and 
educational level, and the lower the HbA1c and treat-
ment with insulin or oral agent at baseline, the higher 
the risk of progression to MetS. To the best of our knowl-
edge, little research has been done to estimate the 
incidence of MetS in patients with T2DM. Therefore, 
we cannot compare our findings with those of other 
studies. The incidence and prevalence rates of MetS in 
general populations in various studies from around the 
world show considerable variation [18, 19]. Estimates 
of the incidence and prevalence of MetS will depend 
upon the methodological factors, the definition of MetS 
used, and the composition of the community exam-
ined by age, gender, ethnicity, and social class, making 
comparisons between studies of limited value. Several 
cross-sectional evaluations, conducted at different times 
and in different populations, have shown considerable 
variation. The prevalence of MetS in people with T2DM 
of 63.2%, as reported in this study, is much higher than 
the value reported in general populations [9, 20–22] 
and similar to the studies on T2DM from other diabetic 
populations [23–25].
The incidence rate of MetS that we report in the 
present study is lower than that reported in low-risk 
population studies carried out in Japan [26], Europe 
[27] and North America [28–30], perhaps due to routine 
diabetes care. Patients with higher BP and dyslipidae-
mia were treated during routine care. The Baltimore 
Longitudinal Study of Aging reported an incidence 
of 25.5% in men and 14.8% in women after an aver-
age follow-up of six years [28]. The Insulin Resistance 
Atherosclerosis Study reported an incidence of 17.1% 
in men and 20.9% in women after a follow-up period 
of five years [29]. A longitudinal study of Japanese men 
aged 35 to 59 reported that the incidence of MetS was 
3.6 per 100 person-years [26]. A longitudinal study of 
Korean male workers aged 30 to 39 reported that the 
incidence of MetS was 77 per 1,000 person-years [31]. 
Another study from an urban area of Portugal reported 
an incidence of 47/1,000 person-years, similar in men 
and women [27]. But this is higher than that reported 
in the San Antonio Heart Study, which showed a 15% 
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incidence of MetS in men and 17% in women after eight 
years of follow-up [30]. The threshold values used to de-
fine the MetS criteria were higher than those indicated 
by NCEP/ATP III for lipids (triglyceride ≥ 200 mg/dL, 
HDL < 35 mg/dL in men and < 45 mg/dL in women) 
and BP (BP ≥ 140/90 mm Hg for systolic and diastolic, 
respectively). However, our findings indicate that 
patients with T2DM appearing to be at higher risk for 
developing MetS do not actually develop it. A possible 
explanation is that these patients may adjust their habits 
toward a healthier lifestyle, besides receiving appropri-
ate treatment for hypertension and hyperlipidaemia.
Several risk factors predicted the incidence of MetS 
in our study. Univariate analysis (Table III) shows 
Table II. Age and age-adjusted means (SE) and proportions of selected baseline characteristics between 1,017 patients with 
type 2 diabetes who did, and 2,030 who did not, develop metabolic syndrome (MetS)
Tabela II. Średnie i skorygowane względem wieku wartości (SE) wybranych parametrów wyjściowych i ich rozkład w grupie 
1017 chorych na cukrzycę typu 2, u których rozwinął się zespół metaboliczny (MetS) i 2030 chorych bez MetS
Variables Developed MetS Did not develop MetS Difference (95% CI)
Mean (SE) Mean (SE)
Age at registration (yr.) 50.8 (0.34) 50.2 (0.24) 0.6 (–0.23, 1.43)
Duration of diabetes (yr.) 6.2 (0.18) 6.4 (0.13) –0.2 (–0.62, 0.32)
Age at diagnosis (yr.) 44.3 (0.18) 44.0 (0.13) 0.3 (0.00, 1.59)
Follow-up (yr.) 11.6 (0.15) 12.0 (0.11) –0.4 (–1.13, –0.39)**
Number of follow-up visits 15.6 (0.41) 9.6 (0.29) 6.0 (5.01, 6.99)**
Height [cm] 159.8 (0.29) 161.5 (0.21) –1.7 (–2.41, –0.99)**
Weight [kg] 66.8 (0.36) 64.0 (0.25) 2.8 (1.68, 3.73)**
BMI [kg/m2] 26.0 (0.12) 24.3 (0.09) 1.7 (1.40, 2.00)**
Systolic BP [mm Hg] 116.1 (0.43) 115.3 (0.31) 0.8 (–0.30, 1.90)
Diastolic BP [mm Hg] 72.4 (0.31) 71.6 (0.23) 0.8 (0.00, 1.56)
Fasting glucose [mg/dL] 203.5 (2.49) 200.0 (1.78) 3.5 (–2.50, 9.50)
HbA1c (%) 8.7 (0.11) 8.6 (0.09) 0.1 (–0.18, 0.38)
Creatinine [mg/dL] 0.94 (0.03) 0.97 (0.02) –0.03 (–0.10, 0.04)
Triglycerides [mg/dL] 162.8 (3.77) 158.3 (2.76) 4.5 (–4.65, 13.70)
Cholesterol [mg/dL] 210.7 (1.48) 205.5 (1.07) 5.2 (–1.61, –8.79)*
HDL cholesterol [mg/dL] 51.0 (0.74) 51.6 (0.68) –0.6 (–2.58, 1.38)
LDL cholesterol [mg/dL] 124.0 (2.44) 121.2 (2.24) 2.8 (–3.51, 9.51)
% %
Men 43.9 50.0 –6.1 (–9.9, –2.4)*
Obesity (BMI ≥ 30) 15.7 8.4 7.3 (4.7, 10.00)**
Dyslipidaemia† 33.6 35.4 –1.8 (–5.4, 1.9)
Current smoker 12.9 19.5 –6.6 (–9.71, –3.61)**
Therapeutic regimen 
Diet 20.7 23.5 –2.8 (–5.81, 0.38)
Oral agent 62.1 60.5 1.6 (–1.97, 5.35)
Insulin 17.1 16.1 1.0 (–1.79, 3.84)
Education
Primary or below 64.2 57.6 6.6 (2.82, 10.30)*
Secondary 25.4 28.0 –2.6 (–5.92, 0.89)
Matriculation or above 10.3 14.4 –4.1 (–6.54, –1.57)*
The difference in the mean or percentage of the variables between MetS and no MetS; *p < 0.01, **p < 0.001, †dyslipidaemia: triglyceride ≥ 150 mg/dL  
(≥ 1.7 mmol/L) or HDL cholesterol < 40 mg/dL (< 0.9 mmol/L) in men or < 50 mg/dl (< 1.0 mmol/L) in women; CI — confidence interval;  
BP — blood pressure; HDL — high-density lipoprotein cholesterol; LDL — low-density lipoprotein cholesterol 
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Table III. Incidence rates and relative risks (RR) for metabolic syndrome by baseline variables
Tabela III. Wskaźniki zapadalności na zespół metaboliczny i ryzyko względne (RR) rozwoju zespołu metabolicznego zależnie 
od wyjściowych wartości badanych parametrów
Variables At risk (n) Cases (n) Person- 
-year
Incidence/1,000 
person-years
Crude RR  
(95% CI)
Age-adjusted RR 
(95% CI)†
All 3,047 1,017 35,677 28.5 – –
Gender
Men 1,461 446 17,205 25.9 1.00 1.00
Women 1,586 571 18,472 30.9 1.19 (1.06, 1.35)** 0.99 (0.84, 1.70)
Age (yr.)
< 40 485 133 5,552 23.9 1.00 –
40–49 946 321 10,603 30.3 1.27 (1.04, 1.54)** –
50–59 946 351 10,732 32.7 1.37 (1.12, 1.66)** –
60–69 508 165 6,700 24.6 1.03 (0.82, 1.29) –
≥ 70 160 47 2,134 22.0 0.92 (0.66, 1.28) –
Age at diagnosis (yr.)
< 30 198 58 2,333 24.9 1.00 –
30–59 2,584 874 30,116 29.0 1.16 (0.90, 1.52) –
 ≥ 60 251 80 3,126 25.6 1.03 (0.74, 1.44) –
Duration of diabetes (yr.)
< 5 1,551 522 17,101 30.5 1.00 1.00
5–7 540 173 6,450 26.8 0.88 (0.74, 1.04) 0.85 (0.77, 0.94)**
8–11 422 143 5,104 28.0 0.92 (0.77, 1.10) 0.79 (0.71, 0.88)***
≥ 12 522 174 6,927 25.1 0.82 (0.70, 0.98) 0.71 (0.65, 0.80)***
Fasting glucose [mg/dL]
< 100 139 51 1,428 35.7 1.00 1.00
≥ 100 2,809 951 33,258 28.6 0.80 (0.61, 1.06) 0.78 (0.66, 0.93)**
HbA1c (%)
< 6.5 258 99 1,407 70.4 1.00 1.00
≥ 6.5 1,034 423 8,667 48.8 0.69 (0.56, 0.86)* 0.51 (0.45, 0.59)***
Systolic BP [mm Hg] 
< 130 2,556 919 28,892 31.8 1.00 1.00
 ≥ 130 348 96 4,410 21.8 0.69 (0.56, 0.84)** 0.90 (0.80, 1.01)
Diastolic BP [mm Hg]
< 85 2,709 966 30,796 31.4 1.00 1.00
 ≥ 85 189 49 2,413 20.3 0.65 (0.49, 0.86)** 0.88 (0.76, 1.02)
Cholesterol [mg/dL]
< 200 1,332 429 14,494 29.6 1.00 1.00
200–219 512 182 6,038 30.1 1.02 (0.86, 1.21) 0.84 (0.76, 0.93)
≥ 220 1,010 373 12,892 28.9 0.98 (0.85, 1.12) 0.75 (0.69, 0.81)***
HDL [mg/dL]
Men ≥ 40 & women ≥ 50 438 210 3,883 54.0 1.00 1.00
Men < 40 & women < 50 106 39 989 39.4 0.73 (0.52, 1.02) 0.85 (0.68, 1.05)
LDL [mg/dL]
< 100 144 57 1,226 46.5 1.00 1.00
≥ 100 388 186 3,533 52.6 1.13 (0.85, 1.51) 0.86 (0.71, 1.05)
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an expected pattern of association for many variables 
with the development of MetS. Participants who 
subsequently developed MetS had greater obesity 
and higher triglycerides, lower smoking and had 
a higher proportion of insulin- or oral agent-treated 
at baseline than those who did not develop MetS. In 
multivariate analysis, fewer remain independently 
associated. The people with T2DM who were insu-
lin- or oral agent-treated were at higher risk of MetS 
than those treated with diet and exercise. Insulin 
or oral agent treatment may indicate a more severe 
disease process. A higher incidence of MetS among 
insulin- or oral agent-treated patients could be attrib-
utable to their longer duration of diabetes, younger 
age at onset, and poorer metabolic control than in 
non-insulin-treated diabetes. Other longitudinal 
studies have documented the pivotal role of obesity 
in the pathogenesis of MetS in different populations, 
although the definition of MetS adopted varied from 
study to study [28, 30].
The lack of correlation between the incidence of 
MetS and elevated BP at baseline in our patients is not 
surprising. In fact, this sort of ‘dissociation’ may affect 
the decision-making process in a clinical setting tailored 
to prevent MetS and cardiovascular events.
The role of gender as a risk factor for MetS remains 
unsettled. There have been conflicting reports about 
the relationship between gender and MetS incidence in 
general populations; in some studies, MetS incidence was 
higher in women [27, 30], whereas in other studies it was 
higher in men [34, 35]. Similar to our results, some other 
cohorts from different ethnic backgrounds have reported 
no significant differences regarding gender [29, 32, 33].
The higher MetS incidence found in lower values 
of HbA1c was probably related to the fact that patients 
with higher values of HbA1c probably are more deficient 
Table III. cont. Incidence rates and relative risks (RR) for metabolic syndrome by baseline variables
Tabela III. cd. Wskaźniki zapadalności na zespół metaboliczny i ryzyko względne (RR) rozwoju zespołu metabolicznego 
zależnie od wyjściowych wartości badanych parametrów
Variables At risk (n) Cases (n) Person- 
-year
Incidence/1,000 
person-years
Crude RR (95% CI) Age-adjusted RR 
(95% CI)†
Triglycerides [mg/dL]
< 150 1,951 693 21,754 31.9 1.00 1.00
 ≥ 150 878 292 11,276 25.9 0.81 (0.71, 0.93)** 0.73 (0.67, 0.79)***
BMI [kg/m2]
< 25 1,688 511 20,077 25.5 1.00 1.00
25–29.9 644 300 6,739 44.5 1.75 (1.52, 2.01)*** 1.24 (1.12, 1.35)***
 ≥ 30 293 153 2,803 54.6 2.14 (1.80, 2.56)*** 1.47 (1.29, 1.67)***
Smoking
Never smoker 1,979 677 25,960 26.1 1.00 1.00
Current smoker 416 100 5,820 17.2 0.66 (0.54, 0.81)*** 0.87 (0.74, 0.98)*
Education
Primary or below 1,718 621 21,273 29.2 1.00 1.00
Secondary 778 246 8,142 30.2 1.03 (0.89, 1.20) 1.25 (1.14, 1.36)***
Matriculation or above 374 100 3,782 26.4 0.90 (0.74, 1.12) 1.37 (1.23, 1.54)***
Creatinine [mg/dL]
≤ 1.5 2,159 823 22,669 36.3 1.00 1.00
> 1.5 61 21 841 25.0 0.69 (0.45, 1.05) 0.60 (0.47, 0.77)***
Therapeutic regimen
Diet 687 211 8,471 24.9 1.00 1.00
Oral agent 1,860 632 21,480 29.4 1.18 (1.01, 1.38)*** 1.25 (1.11, 1.40)***
Insulin 500 174 5,777 30.1 1.21 (0.99, 1.49) 1.20 (1.10, 1.32)***
Total number of patient–years and at risk is not the same for each variable because of missing values; *p < 0.5, **p < 0.01, ***p < 0.001,†relative 
risks (with 95% CI) calculated by Cox’s proportional hazards model; CI — confidence interval; RR — relative risk; BP — blood pressure;  
HDL — high-density lipoprotein cholesterol; LDL — low-density lipoprotein cholesterol
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in insulin and less insulin resistant, which could have 
reduced their probability to present MetS. However, 
this warrants further study.
Some limitations warrant consideration. The Isfa-
han clinical information system for diabetes provides 
one of the largest clinic-based data sets of its kind in 
the developing world. Although we have not carried 
out any special studies of the validity or reliability of 
data for this analysis, a clerk was employed to check 
consistency and, where possible, to ensure complete-
ness of data. Previous studies have shown that these 
patients are a representative sample of the known 
diabetic patients of Isfahan [38]. Our experience with 
other parts of the data set gives us some confidence 
that data quality is sufficient for this type of study and 
that our results provide useful additional evidence on 
the incidence of, and risk factors for, MetS. The study 
was clinic-based, rather than population-based, and 
so may not contain a clinical spectrum representative 
of diabetic patients in the community. Many patients 
requiring only oral or dietary treatment may never at-
tend the clinic. Clinic-based estimates of the incidence 
or prevalence of complications are most likely to be af-
fected by referral patterns. Selection bias is less likely 
to affect incidence rates and associations between risk 
factors and complications as investigated in this study. 
The study was performed according to the modified 
NCEP/ATP III criteria [14]. We used BMI instead of 
waist circumference due to the unavailability of data 
regarding waist circumference in our database. The 
central pattern of distribution, with its higher weight-
ing of waist circumference, is associated with more 
insulin resistance than is the peripheral pattern of 
distribution [37, 38]. Nevertheless, although waist 
measurement is easy and not time-consuming, the 
waist is not routinely measured in clinical practice. 
A number of studies have also shown that BMI is as 
effective as waist circumference for predicting the 
development of T2DM and other metabolic distur-
bances [5, 8, 15, 16]. In addition, the Japan Society 
for the Study of Obesity has reported that BMI can 
estimate visceral fat measured by computed tomog-
raphy as robustly as waist circumference, and that 
obesity-related complications increase for a BMI of 
25 [39]. An additional limitation of the present study 
is represented by the lack of information on the effect 
of medications (lipids lowering and antihyperten-
sive) on the trajectory of MetS components. Despite 
the above limitations, the findings here add to our 
understanding of the incidence, prevalence, risk fac-
tors and the natural course of MetS in patients with 
T2DM in Iran. Furthermore, this study provides new 
data from Iran, a developing country that has been 
under-represented in past studies.
Conclusions
In conclusion, this longitudinal study provides infor-
mation on the high prevalence, but low incidence rate, 
of MetS in patients with T2DM in Isfahan, Iran. Our 
study shows that in routine practice the natural course 
of MetS in patients with T2DM is dynamic. The clinical 
management of patients with T2DM will contribute 
significantly to MetS prevention.
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